These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38693888)

  • 1. Highlight of 2023: Unlocking the therapeutic potential of natural killer cells-advances in adaptive functions, cellular engineering and immunotherapy.
    Lam PY; Souza-Fonseca-Guimaraes F
    Immunol Cell Biol; 2024 Jul; 102(6):444-447. PubMed ID: 38693888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery.
    McErlean EM; McCarthy HO
    J Nanobiotechnology; 2024 Sep; 22(1):552. PubMed ID: 39256765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering Natural Killer Cells for Cancer Immunotherapy.
    Rezvani K; Rouce R; Liu E; Shpall E
    Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer cells and cancer therapy, what we know and where we are going.
    Ghaemdoust F; Keshavarz-Fathi M; Rezaei N
    Immunotherapy; 2019 Oct; 11(14):1231-1251. PubMed ID: 31422725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.
    Daher M; Rezvani K
    Curr Opin Immunol; 2018 Apr; 51():146-153. PubMed ID: 29605760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
    Zhuang X; Long EO
    Trends Immunol; 2019 Dec; 40(12):1078-1081. PubMed ID: 31732285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
    Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
    Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting natural killer cells in cancer immunotherapy.
    Guillerey C; Huntington ND; Smyth MJ
    Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging natural killer cells for cancer immunotherapy.
    Grossenbacher SK; Aguilar EG; Murphy WJ
    Immunotherapy; 2017 May; 9(6):487-497. PubMed ID: 28472904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.
    Bald T; Krummel MF; Smyth MJ; Barry KC
    Nat Immunol; 2020 Aug; 21(8):835-847. PubMed ID: 32690952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Memory-like natural killer cells for cancer immunotherapy.
    Gang M; Wong P; Berrien-Elliott MM; Fehniger TA
    Semin Hematol; 2020 Oct; 57(4):185-193. PubMed ID: 33256911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
    Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
    Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.
    Suck G; Odendahl M; Nowakowska P; Seidl C; Wels WS; Klingemann HG; Tonn T
    Cancer Immunol Immunother; 2016 Apr; 65(4):485-92. PubMed ID: 26559813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cell-mediated immunosurveillance of human cancer.
    Malmberg KJ; Carlsten M; Björklund A; Sohlberg E; Bryceson YT; Ljunggren HG
    Semin Immunol; 2017 Jun; 31():20-29. PubMed ID: 28888619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells: can they be useful as adoptive immunotherapy for cancer?
    Arai S; Klingemann HG
    Expert Opin Biol Ther; 2005 Feb; 5(2):163-72. PubMed ID: 15757378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
    Barrow AD; Colonna M
    Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more.
    Chiossone L; Vienne M; Kerdiles YM; Vivier E
    Semin Immunol; 2017 Jun; 31():55-63. PubMed ID: 28943093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.